DART: An Animal-Free Testing Alternative
Non-animal, non-biopsy, AI-based workstation solution for predicting safety and efficacy in Biopharma and Pharmaceutical industries.
Replacement
DART eliminates the need for animal testing by using AI-driven simulations and in vitro platforms to predict safety concerns during R&D, clinical trials, and production phases.
Reduction
DART supports a gradual reduction in animal testing by providing reliable predictions that decrease the number of animals needed, facilitating a transition to fully animal-free testing methods.
Refinement
DART enhances testing precision and relevance to human physiology, integrating seamlessly into existing workflows and significantly reducing testing time.
Commit to animal cruelty-free testing
With the FDA passing the Modernization Act 2.0 in December 2022 and the European Parliament adopting a resolution to phase out animal testing in September 2022, the need for the shift is more urgent than ever.
DART enables you to predict and manage safety concerns such as neurovirulence, neurotoxicity, and sterility in the workflow during the R&D, clinical trials, and production phases without involving animal experimentation.
Higher relevance to human physiology
No animal experimentation or biopsies
Cost effective modern approach
Enhanced prediction accuracy with ML models
Seamless integration into the company’s existing quality check workflow
Reduction in testing time drastically
Get Human-Relevant Drug Testing Results
DART uses advanced deep-learning neural network algorithms and ethically-sourced human stem cells to generate highly accurate human-relevant scientific data.
Change the traditional way of safety and efficacy assessments
An in-vitro platform that uses a human micro physiological system created from an ethically sourced biobank.
A digital workstation solution to predict safety concerns by comparing with benchmark patterns derived through segmentation model training to provide accurate predictions.
Accelerate Drug Discovery with Dart
Batch Testing
Prediction of neurovirulence and sterility in the vaccine production workflow.
Drug Discovery
Prediction of neurovirulence in viral vaccine development process.
Antivenom Efficacy
Prediction of CAR-T cell therapy-induced neurotoxicity.
Cell-Therapy
Prediction of CAR-T cell therapy-induced neurotoxicity.
Batch Testing
Prediction of neurovirulence and sterility in the vaccine production workflow.
Drug Discovery
Prediction of neurovirulence in viral vaccine development process.
Antivenom Efficacy
Prediction of CAR-T cell therapy-induced neurotoxicity.
Cell-Therapy
Prediction of CAR-T cell therapy-induced neurotoxicity.
Resources
Blogs
Press Releases
Learn More
Thank you for reaching out to us!
Our experts will be in touch with you shortly.
In the meantime, explore our insightful blogs and case studies.
Something went wrong!
Please try it again.